1. Field evaluations of four SARS-CoV-2 rapid antigen tests during SARS-CoV-2 Delta variant wave in South Africa
- Author
-
Natasha Samsunder, Gila Lustig, Slindile Ngubane, Thando Glory Maseko, Santhuri Rambaran, Sinaye Ngcapu, Stanley Nzuzo Magini, Lara lewis, Cherie Cawood, Ayesha BM Kharsany, Quarraisha Abdool Karim, Salim Abdool Karim, Kogieleum Naidoo, and Aida Sivro
- Abstract
Background: Rapid antigen tests detecting SARS-CoV-2 are being increasingly used across the globe and were shown to be a useful tool in managing the COVID-19 pandemic. The purpose of this prospective study was to characterise the performance of four SARS-CoV-2 rapid antigen tests in a South African setting. Methods: Rapid antigen test evaluations were performed through drive-through testing centres in Durban, South Africa from July-December 2021. Two evaluation studies were performed: nasal Panbio COVID-19 Ag Rapid Test Device (Abbott) was evaluated in parallel with the nasopharyngeal Espline SARS-CoV-2 Ag test (Fujirebio, nasopharyngeal); followed by the evaluation of nasal RightSign COVID-19 Antigen Rapid test Cassette (Hangzhou Biotest Biotech) in parallel with the nasopharyngeal STANDARD Q COVID-19 Ag test (SD Biosensor). The Abbott RealTime SARS-CoV-2 assay was used as a reference test. Results: Evaluation of Panbio and Espline Ag tests was performed on 494 samples (31% positivity) while the evaluation of Standard Q and RightTest Ag tests was performed on 539 samples (13.17 % positivity). The overall sensitivity for all four tests ranged between 60-72% with excellent specificity values (>98%). Sensitivity increased to >80% in all tests in samples with Ct value Conclusions: All four evaluated tests detected a majority of the cases within the first week of symptom onset with high viral load and could be a valuable diagnostic tool for controlling the spread of SARS-CoV-2.
- Published
- 2023
- Full Text
- View/download PDF